Pneumonia clinical trials at UC Irvine
5 in progress, 3 open to eligible people
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
open to eligible people ages 18 years and up
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
Orange, California and other locations
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
open to eligible people ages 18-100
The study is a double-blind, randomized, placebo-controlled, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.
Orange, California and other locations
The INSPIRE-ASP PNA Trial
open to eligible people ages 18 years and up
The INSPIRE-ASP PNA trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with PNA is infected with a resistant pathogen. Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.
Riverside, California and other locations
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Sorry, in progress, not accepting new patients
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Irvine, California and other locations
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
Sorry, in progress, not accepting new patients
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in hospitalized subjects with severe or critical COVID-19 pneumonia.
Irvine, California and other locations
Our lead scientists for Pneumonia research studies include Susan Huang, MD, MPH.
Last updated: